Two Los Alamos National Laboratory scientists are among the team recently funded to explore ways to create the precise immune factors needed for effective vaccines against HIV. The Duke University-led consortium will largely concentrate on inducing broadly neutralizing antibodies that can prevent HIV-1 infection, as well as on generating protective T-cell and innate immune system responses.
Researchers at Tufts University School of Engineering have discovered a way to maintain the potency of vaccines and other drugs—that otherwise require refrigeration—for months and possibly years at temperatures above 110 F, by stabilizing them in a silk protein made from silkworm cocoons.
A clinical trial of an Alzheimer's disease treatment developed at Massachusetts Institute of Technology has found that the nutrient cocktail can improve memory in patients with early Alzheimer's. The results confirm and expand the findings of an earlier trial of the nutritional supplement, which is designed to promote new connections between brain cells.
To foster the continued success of the biomanufacturing industry, North Carolina State University has joined forces with a French university to provide biomanufacturing training, education, and process services in the United States and Europe.
A new approach to drug design, pioneered by a group of researchers at the University of California, San Francisco and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects.
At a recent weekend conference of more than 30,000 specialists, experts reported seeing a major escalation in the arms race against cancer. Several new advances, including “smart” drugs, immune system aids, and treatments based on genetic pathways, offer new hope for battling previously intractable diseases.
For 50 years scientists have been unsure how the bacteria that gives humans cholera manages to resist one of our basic innate immune responses. That mystery has now been solved, thanks to research from biologists at The University of Texas at Austin. The answers may help clear the way for a new class of antibiotics that don't directly shut down pathogenic bacteria, but instead disable their defenses so that our own immune systems can do the killing.
Getting a shot at the doctor's office may become less painful in the not-too-distant future. Massachusetts Institute of Technology researchers have engineered a device that delivers a tiny, high-pressure jet of medicine through the skin without the use of a hypodermic needle. The device can be programmed to deliver a range of doses to various depths—an improvement over similar jet-injection systems that are now commercially available.
The U.S. Food and Drug Administration (FDA) generally approves drug therapies faster and earlier than its counterparts in Canada and Europe, according to a new study by Yale University School of Medicine researchers. The study counters perceptions that the drug approval process in the U.S. is especially slow.
Advisers to government health regulators late Thursday recommended that they approve sales of what would be the first new prescription weight-loss drug in the U.S. in more than a decade, despite concerns over cardiac risks.
The superbugs have met their match. Conceived at Nanyang Technological University, it comes in the form of a coating which has a magnetic-like feature that attracts bacteria and kills them without the need for antibiotics.
A cross-disciplinary team of researchers at the University of Maryland has designed a molecular container that can hold drug molecules and increase their solubility, in one case up to nearly 3000 times. Their discovery opens the possibility of rehabilitating drug candidates that were insufficiently soluble.
University of Manchester scientists have discovered an Achilles heel within cells that bacteria are able to exploit to cause and spread infection. The researchers say their findings could lead to the development of new anti-infective drugs as alternatives to antibiotics whose overuse has led to resistance.
Yale University researchers show in detail how three genes within human embryonic stem cells regulate development, a finding that increases understanding of how to grow these cells for therapeutic purposes. This process is different in humans than in mice, highlighting the importance of research using human embryonic stem cells.
An international consortium has determined the structure of an important new drug target in complex with a synthetic molecule designed by University of Bath researchers, opening up new avenues for drug discovery.
Researchers at Brown University and Hasbro Children's Hospital have traced the molecular interactions that allow the protein survivin to escape the nucleus of a breast cancer cell and prolong the cell's life. The study may help in the development of better therapies and prognostics.
In search of ways to fight antibiotic-resistant bacteria, Australian scientists are analyzing synthetic antimicrobial skin secretions of Australian Green-Eyed and Growling Grass frogs. These two species were selected because peptides secreted from their skin form a defense to a broad spectrum of bacteria including Staphylococcus .
The California Institute for Quantitative Biosciences (QB3) has renewed and expanded a three-year agreement with Pfizer Inc. to collaborate on research projects at the University of California (UC) with the potential to transform world-class science into better medicine. Renewal spans 4 UC campuses.
Huntington's disease, the debilitating congenital neurological disorder that progressively robs patients of muscle coordination and cognitive ability, is a condition without effective treatment, a slow death sentence. But if researchers can build on new research, a special type of brain cell forged from stem cells could help restore the muscle coordination deficits that cause the uncontrollable spasms characteristic of the disease.
In preclinical studies, researchers at SRI International and Astraea Therapeutics have recently evaluated the role of a new drug receptor target that shows promise for the treatment of drug addiction. This potential new drug target belongs to a class of receptors called the nicotinic acetylcholine receptors.
Traditional drug manufacturing is a time-consuming process. Active pharmaceutical ingredients are synthesized in a chemical manufacturing plant and then shipped to another site, where they are converted into giant batches of pills. Including transport time between manufacturing plants, each batch can take weeks or months to produce. However, Massachusetts Institute of Technology and Novartis launched a research effort to transform those procedures.
A University of Michigan cell biologist and his colleagues have identified a potential drug that speeds up trash removal from the cell's recycling center, the lysosome. The finding suggests a new way to treat rare inherited metabolic disorders and common neurodegenerative diseases.
The humble aspirin may soon have a new role. Scientists from The City College of New York have developed a new aspirin compound that has great promise to be not only an extremely potent cancer fighter, but even safer than the classic medicine cabinet staple.
Researchers are reporting the first treatment to speed recovery from severe brain injuries caused by falls and car crashes: a cheap flu medicine whose side benefits were discovered by accident decades ago. Severely injured patients who were given amantadine got better faster than those who received a dummy medicine.
A chemically altered osteoporosis drug may be useful in fighting malaria, researchers report in a new study. Unlike similar compounds tested against many other parasitic protozoa, the drug readily crosses into the red blood cells of malaria-infected mice and kills the malaria parasite. The drug works at very low concentrations with no observed toxicity to the mouse.